National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 73793 [2021-28101]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 246 / Tuesday, December 28, 2021 / Notices
patent license will be for the purpose of
consolidating the patent rights to ULRF,
one of the co-owners of said rights, for
commercial development and
marketing. Consolidation of these coowned rights is intended to expedite
development of the inventions,
consistent with the goals of the BayhDole Act codified as 35 U.S.C. 200–212.
The prospective patent license will be
worldwide, exclusive, and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by ULRF will be
subject to the provisions of 37 CFR part
401 and 404.
Griffithsin (GRFT) is a protein that
was originally isolated from marine red
algae, namely Rhodophyte (Griffithsia
sp.). It binds the terminal mannose
residues of N-linked glycans found on
the surface of many enveloped viruses
such as HIV, SARS–CoV, Ebola virus,
and more. The E–029–2022 invention
pertains to novel mutant Griffithsin
(GRFT) formulations and methods of
inhibition of viral infection. The E–030–
2022 invention pertains to methods of
systemically treating viral infections
and additional mutant GRFT variants
that are specifically mutated to
introduce a lysine within a mutant
GRFT sequence. These GRFT variants
can be PEGylated, which significantly
improves pharmacokinetics and
decreases immunogenicity. Based on
current available data, the intended use
for the inventions is as anti-viral
therapies for enveloped virus infections.
This notice is made pursuant to 35
U.S.C. 209 and 37 CFR part 404. The
prospective exclusive patent license
will include terms for the sharing of
royalty income with NCI from
commercial sublicenses of the patent
rights and may be granted unless within
fifteen (15) days from the date of this
published notice the NCI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license
that are timely filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
patent license. In response to this
Notice, the public may file comments or
objections. Comments and objections,
other than those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
VerDate Sep<11>2014
22:45 Dec 27, 2021
Jkt 256001
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: December 21, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2021–28196 Filed 12–27–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
73793
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer Review Branch,
DEA, NIDDK, National Institutes of Health,
6707 Democracy Boulevard, ROOM 7349,
Bethesda, MD 20892–5452 (301) 594–8894,
begumn@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: December 21, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
[FR Doc. 2021–28101 Filed 12–27–21; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel RFA DK–21–503:
Limited Competition for the Continuation of
EDIC Study Research Center (Collaborative
U01, Clinical Trial Not Allowed.
Date: February 14, 2022.
Time: 11:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Democracy II 6707, Democracy Blvd,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
6707 Democracy Boulevard, ROOM 7349,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR10–202: High
Impact Interdisciplinary Science in NODDK
Research Areas (RC2 Clinical Trial Optional)Kidney Diseases.
Date: February 18, 2022.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Democracy II, 6707 Democracy Blvd.
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
BILLING CODE 4140–01–P
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; SBIR Contract Review
Panel.
Date: February 2, 2022.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892.
Contact Person: Rahat (Rani) Khan, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892, 301–594–7319,
khanr2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
E:\FR\FM\28DEN1.SGM
28DEN1
]]>Agencies
[Federal Register Volume 86, Number 246 (Tuesday, December 28, 2021)]
[Notices]
[Page 73793]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-28101]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel RFA DK-21-503: Limited
Competition for the Continuation of EDIC Study Research Center
(Collaborative U01, Clinical Trial Not Allowed.
Date: February 14, 2022.
Time: 11:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Democracy II 6707,
Democracy Blvd, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Najma Begum, Ph.D., Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, 6707
Democracy Boulevard, ROOM 7349, Bethesda, MD 20892-5452, (301) 594-
8894, [email protected].
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; PAR10-202: High Impact
Interdisciplinary Science in NODDK Research Areas (RC2 Clinical
Trial Optional)-Kidney Diseases.
Date: February 18, 2022.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Democracy II, 6707
Democracy Blvd. Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Najma Begum, Ph.D., Scientific Review Officer
Review Branch, DEA, NIDDK, National Institutes of Health, 6707
Democracy Boulevard, ROOM 7349, Bethesda, MD 20892-5452 (301) 594-
8894, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: December 21, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-28101 Filed 12-27-21; 8:45 am]
BILLING CODE 4140-01-P
